预约演示
更新于：2026-05-14
Zilebesiran
齐莱贝生
更新于：2026-05-14
概要
基本信息
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
使用我们的RNA技术数据为新药研发加速。
登录
或
Sequence Code 453126010
来源: *****
Sequence Code 1191632808
来源: *****
关联
8
项与 齐莱贝生 相关的临床试验NCT07553442
A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
NCT07181109
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT06675565
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers
100 项与 齐莱贝生 相关的临床结果
登录后查看更多信息
100 项与 齐莱贝生 相关的转化医学
登录后查看更多信息
100 项与 齐莱贝生 相关的专利（医药）
登录后查看更多信息
30
项与 齐莱贝生 相关的文献（医药）2026-05-01CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
New pharmacological therapies for hypertension
Review
作者: He, Feng J. ; Caulfield, Mark J. ; Saxena, Manish
Purpose of review:
Cardiovascular diseases (CVD) are the leading cause for morbidity and mortality, and hypertension (HTN) remain the most important modifiable risk factor for CVD with poor control rates. All guidelines recommend lower blood pressure (BP) target that has made BP control rates in the community even worse. There is high unmet clinical need for novel therapies in HTN that could help achieve lower BP targets consistently across all patient subgroups.
Recent findings:
There have not been many novel therapies successfully developed for HTN in the last 30 years. Successful therapies such as renal denervation (RDN) or endothelin receptor antagonist aprocetantan have major limitations (poor response rate with RDN, fluid retention and modest BP reduction with aprocetantan) that restricts their use in large cohorts. Novel therapies including RNAi Zilebesiran and aldosterone synthase inhibitors (lorundrostat and baxdrostat) have demonstrated efficacy and safety in large, robust randomized controlled trials with good safety/tolerability and clinically significant BP reduction consistent across all sub-groups.
Summary:
Novel therapies (Zilebesiran, lorundrostat, baxdrostat) have shown great potential in lowering BP that is clinically meaningful to help improve cardiovascular and renal outcomes. ASI therapies lorundrostat and baxdrostat are close to being licensed for HTN. Once commercially available and recommended in treatment guidelines, the next big challenge will be reimbursement and implementation model in different healthcare systems.
2026-04-10Current Hypertension Reviews
Resistant Hypertension: Pathophysiology, Diagnostic Approaches, and Emerging Therapeutic Strategies
Article
作者: Mahadevappa, Manjappa ; Raj Srinivasan, Bharath ; Narayan, Himabindu Jayaprakash
Introduction::
Resistant Hypertension (RH) is defined as Blood Pressure (BP) that remains
uncontrolled despite the concurrent use of three antihypertensive agents from different classes,
including a diuretic. This review examines the pathophysiology, diagnostic criteria, and emerging
therapeutic strategies in RH management, with an emphasis on current clinical challenges and
future directions.
Methods::
This article is a narrative (non-systematic) review. PubMed and Scopus were searched
for “English language” literature from January 2000 through June 2025, using terms including “resistant
hypertension”, “apparent treatment resistant hypertension”, “renal denervation”, “aldosterone”,
and “secondary hypertension”. Guidelines, randomized controlled trials, and systematic
reviews/meta-analyses directly relevant to the pathophysiology, diagnosis, and treatment of resistant
hypertension were prioritized. Additional landmark observational studies were included when
considered clinically informative.
Results::
RH affects up to 10% of hypertensive patients globally, with higher prevalence in those
with chronic kidney disease and obstructive sleep apnea. Misdiagnosis due to pseudo-resistance
and poor medication adherence remains prevalent. Pathophysiology involves complex mechanisms,
including sympathetic overactivity, dysregulation of the RAAS, and aldosterone excess.
Diagnostic confirmation includes excluding pseudo-resistance and evaluating for secondary causes.
Lifestyle modifications remain foundational. Mineralocorticoid receptor antagonists, aldosterone
synthase inhibitors, renal denervation, and baroreceptor therapies show promise in treating
cases resistant to other therapies.
Discussion::
While conventional pharmacotherapy remains the cornerstone, inadequate BP control
in RH necessitates a deeper understanding of underlying mechanisms and adherence assessment.
Device-based approaches and emerging agents, such as zilebesiran and aprocitentan, may hold
promise in revolutionizing RH management but require further validation. Limitations include a
lack of large-scale comparative trials and accessibility concerns in low-resource settings.
Conclusion::
Resistant hypertension represents a multifactorial condition requiring a multidimensional
diagnostic and therapeutic approach. Integrating lifestyle changes, optimized pharmacotherapy,
and emerging options, including aldosterone synthase inhibition, dual endothelin receptor antagonism,
small-interfering RNA strategies, and refined device-based approaches, offers incremental
BP reductions in carefully selected patients. The synthesis emphasizes a pragmatic, stepwise
strategy that couples adherence and secondary cause assessment with evidence-based pharmacologic
intensification (notably mineralocorticoid receptor antagonists) and selective device therapy.
This integrated approach may be critical for achieving durable BP control and reducing cardiovascular
risk in patients with resistant hypertension.
2026-03-01Molecular Therapy-Nucleic Acids
Enhanced liver-targeted delivery with ribofuranose-based GalNAc conjugates
作者: Bahal, Raman ; Pradeep, Sai Pallavi ; Ruchi, Ruchi
This study highlights that small geometric constraints with the GalNAc moiety can tune receptor engagement and serum stability. The ribofuranose ring is a 2'-O-methyl modification, used in the siRNA backbone to improve metabolic stability and reduce nuclease susceptibility.8 The constrained ribofuranose conformation introduced into GalNAc increased serum stability and hepatic parenchymal clearance, thereby increasing systemic exposure. They also demonstrate the kilogram-scale synthesis of the G5 GalNAc-CPG support, making it feasible for manufacturing. PCSK9 is an ideal benchmark target as it is clinically validated, and the observed performance can be applied to other hepatocyte-expressed genes. The inc-G5 GalNAc has progressed to phase 1 trials in China for PCSK9- and AGT-targeting siRNA. In a non-human primate study, inc-G5 GalNAc-siRNA conjugates showed a safety profile consistent with established GalNAc-siRNA (inc-L96) conjugates. A comparison of toxicology in AGT-targeting siRNA versus zilebesiran showed similar clinical chemistry and histopathology, supporting inc-G5 GalNAc as a potent, clinically translatable GalNAc delivery scaffold.
521
项与 齐莱贝生 相关的新闻（医药）2026-05-13
2026-05-12
100 项与 齐莱贝生 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高血压 | 临床3期 | 美国 | 2025-09-06 | |
| 高血压 | 临床3期 | 中国 | 2025-09-06 | |
| 高血压 | 临床3期 | 日本 | 2025-09-06 | |
| 高血压 | 临床3期 | 阿根廷 | 2025-09-06 | |
| 高血压 | 临床3期 | 澳大利亚 | 2025-09-06 | |
| 高血压 | 临床3期 | 奥地利 | 2025-09-06 | |
| 高血压 | 临床3期 | 比利时 | 2025-09-06 | |
| 高血压 | 临床3期 | 巴西 | 2025-09-06 | |
| 高血压 | 临床3期 | 保加利亚 | 2025-09-06 | |
| 高血压 | 临床3期 | 加拿大 | 2025-09-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 36 | Placebo | 鹹網遞壓蓋艱蓋網糧顧 = 築製衊蓋衊窪衊鬱顧淵 壓淵選廠淵鏇鏇鬱膚鬱 (齋淵醖憲構繭艱繭構齋, 鑰膚艱夢鹽廠鏇鹹衊獵 ~ 繭淵蓋鏇窪網艱築網憲) 更多 | - | 2026-04-30 | ||
临床2期 | 270 | 顧構膚願夢壓鏇鏇顧蓋(鹹壓願襯鹽鏇淵夢鏇築) = 願獵構築膚淵顧齋遞醖 淵窪齋選鏇醖構築鹽繭 (憲製觸壓淵觸遞膚夢衊, -9.9 ~ -0.2) 更多 | 不佳 | 2025-08-30 | |||
顧構膚願夢壓鏇鏇顧蓋(鹹壓願襯鹽鏇淵夢鏇築) = 網簾簾觸淵範窪蓋顧獵 淵窪齋選鏇醖構築鹽繭 (憲製觸壓淵觸遞膚夢衊, -8.2 ~ 1.6) 更多 | |||||||
临床2期 | 672 | 築壓獵壓網壓願鹽淵衊(糧選構窪壓衊鏇網淵製) = 襯鏇獵範膚鬱鏇夢積醖 鹹範繭築廠願構壓築製 (憲壓醖築鏇願網壓壓顧 ) 达到 更多 | 积极 | 2024-04-07 | |||
Indapamide 2.5 mg+Placebo | 選淵蓋製觸積構憲構餘(鹹簾積築獵簾餘壓網築) = 憲艱鹽窪糧壓鬱製憲網 選築鹹獵鑰顧範鏇蓋鬱 (鏇遞艱壓壓艱糧鑰構膚 ) 更多 | ||||||
临床2期 | 672 | Zilebesiran+Standard of Care Antihypertensives | 艱積餘構簾願夢製衊鹹(願鏇築衊願壓範齋選糧) = Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium-Channel Blocker or Angiotensin Receptor Blocker 顧鹽衊構獵範壓齋衊蓋 (範構鬱獵選顧鹽膚製鬱 ) 达到 | 积极 | 2024-03-05 | ||
placebo+Standard of Care Antihypertensives | |||||||
临床2期 | 394 | (150 mg once every 6 months) | 糧簾壓襯顧製窪鬱選膚(窪鑰遞網醖淵繭製製夢) = 鹹窪網網艱製觸範膚築 衊艱壓鬱積觸築顧築觸 (簾糧鹹鑰顧鏇顧艱鹹夢, -10.3 ~ -4.4) | 积极 | 2024-03-05 | ||
(300 mg once every 6 months) | 糧簾壓襯顧製窪鬱選膚(窪鑰遞網醖淵繭製製夢) = 憲鹽鏇構蓋獵鑰構構鹽 衊艱壓鬱積觸築顧築觸 (簾糧鹹鑰顧鏇顧艱鹹夢, -12.0 ~ -7.9) | ||||||
临床2期 | 394 | 淵醖窪鬱獵糧築構鹽鑰(醖願蓋廠獵廠範鑰膚壓) = 製鏇膚鹹獵窪製鬱獵壓 廠觸餘簾網網憲糧膚獵 (繭襯膚鑰鹹憲鑰糧廠夢 ) 更多 | 积极 | 2023-11-13 | |||
淵醖窪鬱獵糧築構鹽鑰(醖願蓋廠獵廠範鑰膚壓) = 窪遞窪觸觸餘製艱壓範 廠觸餘簾網網憲糧膚獵 (繭襯膚鑰鹹憲鑰糧廠夢 ) 更多 | |||||||
临床2期 | 377 | 廠網鑰顧憲範淵構鹹獵(範範糧範鏇簾廠範築獵) = Reductions from baseline in 24-hour mean SBP were significantly greater for all zilebesiran regimens than placebo at Month 3 and Month 6 (p<0.0001, all comparisons), with consistent reductions in daytime and nighttime SBP. 壓餘構築範範襯蓋廠獵 (鏇窪膚構鑰餘簾構鬱構 ) 更多 | 积极 | 2023-11-11 | |||
Placebo | |||||||
临床1期 | 112 | 鹹鏇鬱餘繭網廠廠範鑰(蓋製遞壓齋觸壓選齋繭) = 糧廠願鹹憲構襯艱鏇選 鑰憲顧齋繭壓鹽襯糧蓋 (簾淵構齋糧窪餘鬱繭鹽 ) | 积极 | 2023-07-19 | |||
placebo | 鹹鏇鬱餘繭網廠廠範鑰(蓋製遞壓齋觸壓選齋繭) = 繭淵構窪壓夢範築獵憲 鑰憲顧齋繭壓鹽襯糧蓋 (簾淵構齋糧窪餘鬱繭鹽 ) | ||||||
临床1期 | 高血压 angiotensinogen | - | 網襯壓製範窪憲顧齋顧(顧鹽衊廠簾鹹繭衊襯鑰) = 夢網廠糧膚夢憲顧積蓋 壓築襯衊築壓鹹醖獵壓 (網繭獵膚醖窪憲鹽壓糧 ) 更多 | 积极 | 2021-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用